Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients

Table 1 Treatment outcomes with zoledronic acid

Patient	Sites of disease^a	PFS^b (months)	Additional therapy	Status at last visit	OS^b (months)
1	Lung	20	Pazopanib/surgery	NED	63+
2	Lung	54+	None	NED	54+
3	Lung and hilum	18	Radiation to hilum/neurosurgery	SD	59+
4	Lung	14+	None	SD	14+
		Median 19			Median 56+

PFS progression-free survival; OS overall survival; NED no evidence of disease; SD stable disease
^asites of osteosarcoma active during or immediately preceding ZA
^bcalculated from start of ZA

ISSN: 2045-3329